Trial Profile
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Zibotentan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Mar 2010 Actual patient number (22) added and actual initiation date (June 2003) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
- 30 Nov 2006 Status change